Here at Innoture, the key to our future is to always drive innovation forward and we are on a mission to make a meaningful difference to improve patient and public health globally.



We are focused on the design and development of innovative microneedle technology for use with vaccines, medicines, aesthetics, and diagnostic testing.


Our next generation of delivery to overcome current supply chain and logistical challenges whilst improving patient experience to more effectively stimulate the immune system in therapy areas including infectious diseases and oncology.


A breakthrough for both new and approved prescription medicines (e.g. dermatology, cardiovascular & gastroenterology and more). Also enable patients to self-care with novel over-the-counter products for pain relief, anti-allergy, health supplements and many more.


Award winning, ergonomic delivery devices with proven efficacy to improve skin quality and texture. Established and validated manufacturing capabilities.


Exploring potential as a user-friendly diagnostic tool for pregnancy testing or continuous monitoring for chronic conditions such as diabetes and cardiovascular disease.


Actively exploring opportunities with pharmaceutical industry, academic and NGO partners to research, develop and commercialise the next generation of transformational treatments, truly focused on the patient, across a wide spectrum of therapy areas.

Ken Jones

Ken Jones

Chief Executive Officer

With over 35 years of global pharmaceutical & medical device industry experience, Ken was appointed CEO at Innoture in 2016, with a mission to drive future growth.

Former President and CEO of Astellas Pharma Europe, he has also worked for companies including Allergan, Yamanouchi, and SmithKline.

Experienced executive in leading and growing organisations. Specialises in developing and successfully launching first-in-class and borderline products to international markets.

Dr John Bolodeoku

Dr John Bolodeoku

Chief Medical Officer

Ensuring all our product development is “patient centric” John is an Honorary Consultant Physician, Pharmaceutical Physician and Chemical Pathologist and Fellow of the Royal College of Pathologists, with a PhD in Molecular Pathology from Oxford University.

With extensive therapy area and diagnostics experience, he previously held global roles in pharmaceutical companies and Clinical Research Organisations including Pfizer, Yamanouchi, Astellas, NAPP, Daiichi Sankyo, Celgene, Roche, Lilly and Biogen, BIOS and ICON Solutions.

Ryan Bamsey

Ryan Bamsey

Head of Technology & Development

Ryan drives the planning and implementation of all our development projects. A manufacturing specialist, he is a Prince2 Practitioner with complex project management experience, having previously worked at Boots Centre for Innovation and British Biocell.

With a passion for driving quality assurance and compliance, he is also leading on implementation of international standards (ISO13485 & ISO9001).

Henry King

Henry King

Head of Corporate Development & Communications

Henry leads the global corporate strategy and our business development activities to establish industry partnerships. He also heads our alliance management and communications teams.

Previous venture capital and medical agency experience included successful management of global programs for clients from leading pharmaceutical companies.


When Innoture was first established back in 2011, we initially focused our efforts on the commercialisation of cosmetic products, and in 2016, we launched the multi award winning skincare brand Radara.

Currently available in 33 European countries, Radara’s solid microneedle patches contain specially formulated hyaluronic acid serum and target reduction of fine lines and wrinkles around the eyes.


We welcome discussions with potential industry, academic and NGO partners as to how we can combine your molecule with our technology to make a meaningful difference to patient and public health.

Do get in touch if you would like to join us on this journey.